Anti-Prostate Cancer Agents walks the readers through the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications. This book covers discovery/design, synthetic studies, preclinical evaluation, mechanism of action, structure-activity relationships, clinical studies/applications of anti-prostate cancer agents.
This book provides insight on how the design and discovery process of anti-prostate cancer agents have evolved from androgen deprivation therapy to current androgen receptor antagonists/degraders. So far, no book focusing on the topic has been published.
1. Chapter 1. Introduction: Overview of prostate cancer - p. 1 2. Chapter 2. FDA-approved therapeutics and diagnostics for prostate cancer - p. 21 3. Chapter 3. Androgen deprivation therapy - p. 79 4. Chapter 4. Antiprostate cancer agents interacting with topoisomerase II - p. 91 5. Chapter 5. Microtubule-stabilizing compounds as antiprostate cancer agents - p. 111 6. Chapter 6. Comprehensive insights into androgen receptor structure, signaling, and targeted therapeutics in prostate cancer - p. 135 7. Chapter 7. Androgen biosynthesis suppressors in prostate cancer therapy - p. 159 8. Chapter 8. Androgen receptor antagonists: From steroidal to first-generation nonsteroidal agents - p. 181 9. Chapter 9. Second-generation nonsteroidal androgen receptor antagonists - p. 199 10. Chapter 10. Antiprostate cancer agents: Focus on N-terminal domain of androgen receptor - p. 223 11. Chapter 11. Androgen receptor degraders as antiprostate cancer agents - p. 241 12. Chapter 12. Radiotherapeutics in prostate cancer therapy - p. 277 13. Chapter 13. Immunotherapy for prostate cancer - p. 291 14. Chapter 14. Radiosensitizers for prostate cancer therapy - p. 309 15. Chapter 15. Prostate-specific membrane antigen in prostate cancer: Diagnostic and therapeutic innovations - p. 333 16. Chapter 16. PARP inhibitors in prostate cancer: Mechanism, therapeutics, and clinical perspectives - p. 355 17. Chapter 17. Combination therapies for prostate cancer: Synergistic approaches - p. 373 18. Chapter 18. Future directions - p. 397 19. Index - p. 419
Anti-Prostate Cancer Agents walks the readers through the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications. This book covers discovery/design, synthetic studies, preclinical evaluation, mechanism of action, structure-activity relationships, clinical studies/applications of anti-prostate cancer agents.
This book provides insight on how the design and discovery process of anti-prostate cancer agents have evolved from androgen deprivation therapy to current androgen receptor antagonists/degraders. So far, no book focusing on the topic has been published.
1. Chapter 1. Introduction: Overview of prostate cancer - p. 1 2. Chapter 2. FDA-approved therapeutics and diagnostics for prostate cancer - p. 21 3. Chapter 3. Androgen deprivation therapy - p. 79 4. Chapter 4. Antiprostate cancer agents interacting with topoisomerase II - p. 91 5. Chapter 5. Microtubule-stabilizing compounds as antiprostate cancer agents - p. 111 6. Chapter 6. Comprehensive insights into androgen receptor structure, signaling, and targeted therapeutics in prostate cancer - p. 135 7. Chapter 7. Androgen biosynthesis suppressors in prostate cancer therapy - p. 159 8. Chapter 8. Androgen receptor antagonists: From steroidal to first-generation nonsteroidal agents - p. 181 9. Chapter 9. Second-generation nonsteroidal androgen receptor antagonists - p. 199 10. Chapter 10. Antiprostate cancer agents: Focus on N-terminal domain of androgen receptor - p. 223 11. Chapter 11. Androgen receptor degraders as antiprostate cancer agents - p. 241 12. Chapter 12. Radiotherapeutics in prostate cancer therapy - p. 277 13. Chapter 13. Immunotherapy for prostate cancer - p. 291 14. Chapter 14. Radiosensitizers for prostate cancer therapy - p. 309 15. Chapter 15. Prostate-specific membrane antigen in prostate cancer: Diagnostic and therapeutic innovations - p. 333 16. Chapter 16. PARP inhibitors in prostate cancer: Mechanism, therapeutics, and clinical perspectives - p. 355 17. Chapter 17. Combination therapies for prostate cancer: Synergistic approaches - p. 373 18. Chapter 18. Future directions - p. 397 19. Index - p. 419
